This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Urologix Reports Results For Fiscal Year 2011 Second Quarter

MINNEAPOLIS, Jan. 25, 2011 (GLOBE NEWSWIRE) -- Urologix®, Inc. (Nasdaq:ULGX), the manufacturer and marketer of minimally invasive Cooled ThermoTherapy™ (CTT), the durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the second quarter of its fiscal year 2011 that ended December 31, 2010.

Fiscal year 2011 second-quarter revenue was $3.3 million, down 1 percent from the $3.4 million reported in the first quarter of fiscal year 2011 and down 18 percent compared to the $4.1 million reported for the same period of the prior fiscal year. The sequential decrease in revenue was largely due to reduced order volume from our current customer base. There has been no material difference in the percentage of overall catheter revenue derived from our various sales channels (direct, mobile, third party mobile) compared with the first quarter of fiscal year 2011. On a year-over-year basis, the sales comparison is impacted by the temporary market withdrawal of a competitive product.

For its fiscal year 2011 second quarter, Urologix posted a net loss of $712,000, or $0.05 per diluted share, on revenue of $3.3 million. This compares to a net loss of $708,000, or $0.05 per diluted share, in the first quarter of fiscal year 2011 and a net loss of $273,000, or $0.02 per diluted share, in the second quarter of the prior fiscal year. 

"We are pleased that Medicare has stabilized reimbursement for the next twelve months as we enter our third fiscal quarter and the beginning of a new calendar year," stated Stryker Warren jr, CEO. "With the improved clarity on reimbursement and a reportedly improving economy we must be able to leverage our sales force to drive growth. We are committed to succeeding this quarter in growing our revenue by continuing to present Urologix' Cooled ThermoTherapy to urologists as the early therapeutic choice to treat BPH patients versus chronic medication."

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.26 -0.77%
FB $101.50 2.00%
GOOG $684.03 0.87%
TSLA $163.06 10.00%
YHOO $27.10 1.00%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs